Laddar...
A new oral testosterone undecanoate therapy comes of age for the treatment of hypogonadal men
BACKGROUND: A novel formulation of oral testosterone undecanoate (TU) was studied in a long- and short-term phase III trial to evaluate safety and efficacy. METHODS: Hypogonadal men (age 18–65 years; two morning serum testosterone (T) <300 ng/dl with signs/symptoms) were recruited into a 365 day...
Sparad:
| I publikationen: | Ther Adv Urol |
|---|---|
| Huvudupphovsmän: | , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
SAGE Publications
2020
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7328356/ https://ncbi.nlm.nih.gov/pubmed/32655691 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756287220937232 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|